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Abstract
Background: The link between eosinophils and the development of airway hyperresponsiveness
(AHR) in asthma is still controversial. This question was assessed in a murine model of asthma in
which we performed a dose ranging study to establish whether the dose of steroid needed to
inhibit the eosinophil infiltration correlated with that needed to block AHR.
Methods: The sensitised BALB/c mice were dosed with vehicle or dexamethasone (0.01–3 mg/kg)
2 hours before and 6 hours after each challenge (once daily for 6 days) and 2 hours before AHR
determination by whole-body plethysmography. At 30 minutes after the AHR to aerosolised
methacholine the mice were lavaged and differential white cell counts were determined.
Challenging with antigen caused a significant increase in eosinophils in the bronchoalveolar lavage
(BAL) fluid and lung tissue, and increased AHR.
Results: Dexamethasone reduced BAL and lung tissue eosinophilia (ED50 values of 0.06 and 0.08
mg/kg, respectively), whereas a higher dose was needed to block AHR (ED50 of 0.32 mg/kg at 3 mg/
ml methacholine. Dissociation was observed between the dose of steroid needed to affect AHR in
comparison with eosinophilia and suggests that AHR is not a direct consequence of eosinophilia.
Conclusion: This novel pharmacological approach has revealed a clear dissociation between
eosinophilia and AHR by using steroids that are the mainstay of asthma therapy. These data suggest
that eosinophilia is not associated with AHR and questions the rationale that many pharmaceutical
companies are adopting in developing low-molecular-mass compounds that target eosinophil
activation/recruitment for the treatment of asthma.
Introduction
Airway inflammation and hyperresponsiveness (AHR) are
recognised as major characteristics of bronchial asthma;
however, their relationship is still poorly understood. Ex-
posure to allergen causes an increase in airway responsive-
ness that is associated with an influx of inflammatory
cells, particularly eosinophils, into the airways in allergic
humans [1] and sensitised mice [2], which suggests a caus-
al relationship between airway inflammation and AHR
[3,4]. However, there is also much published literature
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suggesting that there is no relationship between allergic
airway inflammation and AHR.
In this study we wished to determine whether there was a
dissociation between the effective dose of a steroid, dex-
amethasone, needed to affect antigen-induced AHR in
comparison with that needed to affect airway inflamma-
tion in the mouse. We have previously described a murine
model of asthma that includes non-specific AHR and as-
sociated eosinophilia in the airways [5]. In the present
study we followed the same sensitising and challenging
protocol but decided to determine AHR in conscious,
spontaneously breathing, unrestrained mice by whole-
body plethysmography [6–9]. Airway responsiveness was
expressed as enhanced pause (Penh), a calculated value,
which is an indirect measurement that is correlated with
measurement of airway resistance, impedance and intrap-
leural pressure in the same animal [6]. This method was
chosen instead of our previously used invasive method
because it might offer several potential advantages: it is
technically less demanding, it allows repeated measure-
ments over a long period and it avoids the use of anaes-
thetic and mechanical ventilation. However, one possible
disadvantage is that one cannot rule out a contribution by
the nose and upper respiratory tract to the parameters
measured. This method of antigen-induced airway in-
flammation and AHR is very similar to that of Dohi et al.
[9] in which they report a strong correlation between Penh
and eosinophil number in bronchoalveolar lavage (BAL)
fluid.
Materials and methods
Animals
Male Balb/C mice (14–16 g, 5 weeks old), were obtained
from Harlan (Bicester, Oxon., UK), and housed for 1 week
before experiments were initiated. Food and water were
supplied ad libitum. Experiments were performed in ac-
cordance with the UK Home Office guidelines for animal
welfare based on the Animals (Scientific Procedures) Act
1986.
Study design
The aim of this study was to determine whether there was
dissociation between the effective dose of a steroid needed
to affect antigen-induced airway inflammation and AHR.
Sensitisation and antigen challenge protocol
Mice were immunised on days 0 and 14 by intraperitoneal
(i.p.) injection of 10 µg of ovalbumin (Grade V; Sigma-
Aldrich, Poole, Dorset, UK), in 0.2 ml of saline (Fresenius
Kabi, Warrington, Cheshire, UK) with 20 mg of alumini-
um hydroxide (Merck, Lutterworth, Leicester, UK). From
day 21 the animals were challenged with aerosolised oval-
bumin (5% in saline) or vehicle (saline) for 20 minutes
per day on six consecutive days. Aerosol generation was
achieved by use of an air-driven nebuliser (System 22;
Medic-aid, Pagham, West Sussex, UK).
Administration of dexamethasone
Vehicle (1% carboxymethylcellulose [Merck, Lutterworth,
Leics., UK] in distilled water) or dexamethasone (Sigma-
Aldrich) was administered twice daily by the oral route in
a dose volume of 10 ml/kg (0.01–3 mg/kg), the day be-
fore the first ovalbumin challenge, 2 hours before and 6
hours after subsequent challenges and on the morning of
the AHR determination.
Airways mechanics measurements in nonrestrained, 
conscious mice
Twenty-four hours after the last ovalbumin challenge,
mice were placed in a whole-body plethysmograph to fa-
cilitate the measurement of lung function as described by
Tsuyuki  et al. [7]. Bronchoconstriction to aerosolised
methacholine (MCh) (3 or 10 mg/ml for 60 seconds with
5 minute intervals) (Sigma-Aldrich) was determined.
Inflammatory cells in the lung
One hour after the last MCh challenge the mice were
killed by anaesthetic overdose (pentobarbitone sodium,
200 mg/kg; Rhone Merieux, Harlow, Essex, UK). BAL was
performed with three 0.3 ml aliquots of Roswell Park Me-
morial Institute medium (RPMI 1640; Life Technologies,
Paisley, Renfrewshire, UK). The lungs were removed, and
were then cleaned and finely chopped after blood had
been perfused out. The chopped tissue was then digested
enzymatically to obtain inflammatory cells, as described
by Underwood et al. [10]. Total counts of cells recovered
in the BAL fluid and tissue digest were made with an au-
tomated cell counter (Sysmex F-820; Sysmex UK, Linford
Wood, Bucks., UK). Differential counts of cells (eosi-
nophils, neutrophils, macrophages, monocytes and lym-
phocytes) recovered in the samples were made by light
microscopy, of cytocentrifuge preparations (100 µl aliq-
uots spun at 700 rpm for 5 minutes at low acceleration)
(Cytospin; Shandon Scientific, Runcorn, Cheshire, UK),
which had been stained with Wright-Giemsa stain (Sig-
ma-Aldrich), with a Hematek 2000 (Ames Co., Elkhart,
Indiana, USA).
Statistical analysis
All values are presented as means ± SEM per group with n
= 10. ED50 values stated are defined as the amount of drug
required to elicit 50% of the maximum inhibition. Statis-
tical analysis was made by analysis of variance with a cor-
rection for multiple comparisons. P < 0.05 was considered
to be statistically significant.Respir Res 2003, 4 http://www.respiratory-research/content/4/1/3
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Results
Inflammatory cells in the lung
Antigen challenge caused a significant increase in eosi-
nophils recovered in the BAL fluid and lung tissue. Dex-
amethasone evoked a significant dose-related inhibition
of antigen-induced eosinophilia in the BAL fluid and lung
tissue, with ED50 values of 0.08 and 0.06 mg/kg, respec-
tively (Fig. 1 and Table 1). The higher doses of dexameth-
asone almost completely abolished BAL eosinophilia but
inhibited tissue eosinophilia only by about 50%.
Antigen challenge also significantly increased neutrophil,
monocyte and lymphocyte numbers in BAL fluids, and
neutrophil, macrophage, monocyte and lymphocyte
numbers in lung tissue (Table 2). This increase in num-
bers of inflammatory cells was significantly inhibited by
dexamethasone treatment, although the effect on tissue
neutrophilia did not reach statistical significance (Tables
1 and 2).
Airway responsiveness
There was no change in basal Penh after multiple antigen
challenge when compared with saline controls and there
was no effect of dexamethasone treatment on basal Penh at
the doses tested. Antigen challenge significantly increased
airway responsiveness to inhaled MCh compared with sa-
line controls. Dexamethasone treatment significantly in-
hibited AHR (Fig. 2A depicts peak changes after 3 mg/ml
MCh). Figure 2B represents an effective dose of dexameth-
asone (1 mg/kg) on all of the concentrations of MCh in-
cluding positive and negative controls. A higher dose of
dexamethasone was needed to block AHR than eosi-
nophilia when ED50 values are compared (Table 1).
Discussion
In this study we have shown for the first time that there is
dissociation between the dose of steroid needed to affect
antigen-induced BAL and lung tissue eosinophilia and
that needed to affect AHR. The ED50 dose of dexametha-
sone required to inhibit AHR is higher than that needed to
inhibit eosinophilia. It is possible that eosinophilia has to
be completely inhibited to have an effect on AHR; indeed,
at 1 mg/kg dexamethasone, eosinophil infiltration into
the BAL fluid following challenge is almost completely
blocked and at the same dose AHR is also completely re-
versed. Lung tissue eosinophilia, however, is only inhibit-
ed by about 50% at 1 mg/kg dexamethasone, which
further indicates the dissociation between eosinophilia
and AHR. De Bie et al. [11] showed that dexamethasone
(0.5 mg/kg) inhibited both antigen-induced AHR and air-
way eosinophilia in the mouse; however, using similar
doses we found only an effect on eosinophilia. In the
study by De Bie et al. [11] they administered the steroid
intraperitoneally and employed a different way of meas-
uring AHR, which might account for the difference.
Throughout the literature there are reports of various in-
terventions that affect both allergic AHR and eosinophilia.
Antibodies against interleukin-5 (IL-5) have been shown
to inhibit both AHR and eosinophilia in the mouse [12–
14]. Both allergic AHR and eosinophilia have been shown
to be reduced in the following cases: in mice deficient in
ICAM-1 (intercellular cell-adhesion molecule-1) [15] by
treatment with an anti-B7-2 (CD86) monoclonal anti-
body [7,16] and with an anti-CTLA4-IgG [17]; in Vβ8+-de-
ficient mice and BALB/c mice treated with antibodies
against Vβ8 [18]; in mice lacking a functioning 5-lipoxy-
genase enzyme [19]; in interferon-β-treated mice [20]; in
IL-12 treated mice [21,22]; and in mice treated with an
immunosuppressive agent, FK-506 [8].
Figure 1
Effect of dexamethasone treatment on BAL (A) and lung tis-
sue (B) eosinophil number 24 hours after the last antigen 
challenge in sensitised mice. Results represent mean ± s.e.m. 
(n = 10). * P < 0.05 compared with relevant vehicle dosed 
control group.
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There are reports of interventions inhibiting allergic eosi-
nophilia but not AHR: in humans, an IL-5-blocking mon-
oclonal antibody [23]; in mice, antibodies against IL-5
[24–26] and IL-5 knockout animals [27]. Other interven-
tions have been shown to have the reverse effect, inhibit-
ing allergic AHR without affecting eosinophilia:
antibodies against interferon-γ in mice [26], antibodies
against IL-16 in mice [28], IL-10-deficient mice [29] and
mast-cell-deficient mice [24,25]; Tournoy et al. [30]
showed that by lowering the allergic challenge eosi-
nophilia was lost but AHR remained.
Treatment with dexamethasone inhibited other leuko-
cytes measured in the lung with ED50 values comparable
to those determined for eosinophilia (Table 1). This
would suggest that these inflammatory cells are also not
associated with AHR; indeed, neutrophil numbers in the
BAL fluid and tissue were not reduced to unchallenged
levels by any dose of steroid used here (Table 2), whereas
AHR was completely reversed. The involvement in AHR of
other leukocytes measured here cannot be completely
ruled out because it might be necessary to completely in-
hibit their infiltration into the lung before any impact on
AHR is observed. Increased levels of macrophages, mono-
cytes and lymphocytes in the lung were only completely
inhibited at 1 mg/kg of dexamethasone, which is the cor-
responding dose needed to block AHR.
There is therefore a wealth of literature on the association
between allergic eosinophilia and AHR that is sometimes
Table 1: Effect of dexamethasone treatment on inflammatory cell numbers in bronchoalveolar lavage (BAL) fluid and lung tissue after 
the last antigen challenge in sensitised mice
Parameter Eosinophils Neutrophils Macrophages Monocytes Lymphocytes MCh challenge (3 mg/ml)
BAL ED50 0.08 0.14 - 0.09 0.10 -
Tissue ED50 0.06 - 0.13 0.13 0.08 -
AHR peak changes, ED50 - - - - - 0.35
AHR AUC changes, ED50 - - - - - 0.32
Results are expressed as ED50 values, in mg/kg of dexamethasone. AHR, airway hyperresponsiveness; AUC, area under the curve; MCh, 
methacholine.
Table 2: Effect of dexamethasone treatment on inflammatory cell numbers in bronchoalveolar lavage (BAL) fluid and lung tissue after 
the last antigen challenge in sensitised mice
Cell type Vehicle saline Vehicle OA Dex 0.01 OA Dex 0.03 OA Dex 0.1 OA Dex 0.3 OA Dex 1 OA Dex 3 OA
BAL 
eosinophils
0.6 ± 0.2 180.3 ± 34.6* 239.8 ± 76.5 129.9 ± 45.3 66.9 ± 20.6 43.6 ± 11.5* 4.6 ± 1.7* 3.6 ± 2.1*
BAL 
neutrophils
0.7 ± 0.3 449.4 ± 76.7* 617.9± 196.7 335.2 ± 93.9 218.8 ± 59.5 173.6 ± 46.8 38.5 ± 11.2* 29.8 ± 10.2*
BAL 
macrophages
104.4 ± 16.5 68.6 ± 12.7 79.9 ± 14.2 91.5 ± 14.2 57.0 ± 11.3 65.5 ± 5.5 71.7 ± 10.5 70.9 ± 4.7
BAL 
monocytes
10.2 ± 2.0 62.4 ± 8.5* 68.6 ± 19.5 52.2 ± 14.0 37.7 ± 9.2 25.8 ± 6.5 6.1 ± 1.0* 6.6 ± 1.6*
BAL 
Lymphocytes
6.2 ± 1.8 80.4 ± 12.9* 111.5 ± 39.1 62.3 ± 18.0 37.4 ± 13.0 28.2 ± 6.7 5.6 ± 1.2* 6.9 ± 1.7*
Tissue 
eosinophils
823 ± 108 4944 ± 715* 5480 ± 1323 4033 ± 734 3479 ± 713 2703 ± 328* 2557 ± 519* 2739 ± 476*
Tissue 
neutrophils
4948 ± 622 21869 ± 2756* 22884 ± 4686 22261 ± 5450 16166 ± 2473 14520 ± 1767 15188 ± 1750 18619 ± 1805
Tissue 
macrophages
571 ± 95 4721 ± 1277* 4590 ± 1266 3602 ± 754 2887 ± 841 2267 ± 714 689 ± 239* 311 ± 125*
Tissue 
monocytes
367 ± 78 6889 ± 1316* 7946 ± 2196 5524 ± 1524 3923 ± 993 2737 ± 1168 304 ± 69* 196 ± 75*
Tissue 
lymphocytes
1069 ± 98 8277 ± 1327* 8292 ± 2638 5912 ± 1696 3990 ± 959 3440 ± 959 707 ± 156* 691 ± 116.5*
The concentration of cells in BAL fluid was 103/ml (the volume of BAL recovered in the lavage in this experiment was 0.6 ml from each animal) and 
that of tissue cells was 103/mg of tissue. Results are means ± SEM (n = 10). Asterisks indicate a significant difference (P < 0.05) from the relevant 
vehicle-dosed control group. OA, Ovalbumin.Respir Res 2003, 4 http://www.respiratory-research/content/4/1/3
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confusing and contradictory. This is the first study that has
addressed this question with a range of doses of corticos-
teroid, compounds known to block AHR and eosi-
nophilia in all animal models of asthma and to affect
inflammation and AHR in asthmatics in a clinical setting.
We feel that this novel pharmacological approach has re-
vealed a clear dissociation between eosinophilia and AHR
in the same animal and this concurs with a study in hu-
mans showing no correlation between AHR and the
number of inflammatory cells in sputum or
bronchoalveolar lavage [31]. These data question the ra-
tionale that many pharmaceutical and biotechnology
companies have adopted in embarking on drug discovery
programmes that target the eosinophil activation/infiltra-
tion signalling pathways (e.g. IL-5, VLA-4 and CCR-3).
These data suggest that other factors, such as airway wall
remodelling, activation state of the eosinophils, T-cell ac-
tivation or autonomic dysfunction, might be more impor-
tant in the development of AHR.
Conclusion
Dissociation was observed between the dose of steroid
needed to affect AHR compared with that required to af-
fect inflammation, suggesting that AHR is not a direct con-
sequence of eosinophilia. This novel pharmacological
approach has revealed a clear dissociation between eosi-
nophilia and AHR by using steroids that are the mainstay
of asthma therapy. If the eosinophil is not associated with
AHR, as this result suggests, the information described
here is vitally important given that many pharmaceutical
companies are engaged in developing low-molecular-
mass compounds that target eosinophil activation/re-
cruitment for the treatment of asthma.
Abbreviations
AHR = airway hyperresponsiveness; BAL = bronchoalveo-
lar lavage; IL = interleukin; i.p. = intraperitoneal; MCh =
methacholine; Penh = enhanced pause.
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